603351 Nanjing Well Pharmaceutical Group
- 20.69
- +0.33+1.62%
Nanjing Well Pharmaceutical Group News
Earnings Growth of 25% Over 1 Year Hasn't Been Enough to Translate Into Positive Returns for Nanjing Well Pharmaceutical GroupLtd (SHSE:603351) Shareholders
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. For example, the Nanjing Well Pha
Nanjing Well Pharmaceutical Group (603351.SH) will pay a dividend of 0.3 yuan per share for the 2023 fiscal year, with the equity registration date set for June 12.
Nanjing Well Pharmaceutical Group (603351.SH) announced that the company will distribute annual equity dividends for 2023, with a cash dividend of 0.3 yuan per share (including tax), and the record date is June 12th.
Well Pharmaceutical (603351.SH): Zou Jianguo plans to reduce holdings by no more than 9,300 shares
On May 21, Ge Longhui Pharmaceutical (603351.SH) announced that Mr. Zou Jianguo plans to reduce his total holdings of the company's shares by no more than 9,300 shares within 6 months after 15 trading days from the date of disclosure of the announcement, that is, no more than 0.0069% of the company's total share capital, or 25% of the total number of shares directly held by the company.
Well Pharmaceutical (603351.SH) released 2023 annual results, with net profit of 112 million yuan, an increase of 18.07% over the previous year
Well Pharmaceutical (603351.SH) released its 2023 annual report. The company achieved operating income of 11 during the reporting period...
Nanjing Well Pharmaceutical GroupLtd (SHSE:603351) Is Reinvesting At Lower Rates Of Return
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in c
Weir Pharmaceutical (603351.SH): Termination of issuance of convertible corporate bonds to unspecified targets and withdrawal of application documents
Gelonghui, January 31 | Well Pharmaceutical (603351.SH) announced that since the company applied for this distribution, the company and intermediaries have actively promoted related work. In view of factors such as changes in the current market environment and the company's own actual situation, after careful analysis, research and communication, the company decided to stop issuing convertible corporate bonds to unspecified targets and withdraw the relevant application documents.
[BT Financial Report Instantaneous Analysis] Weir Pharmaceutical's 2023 Three-Quarter Report: A Financial Perspective Behind Steady Growth
Nanjing Well Pharmaceutical Group Co., Ltd. (stock code: 603351) is an enterprise that has been deeply involved in the field of pharmaceutical excipients and synthetic lubricant base oil products for many years. The company relies on core technology to provide high-quality products for the pharmaceutical and lubricant industries. In the face of policy advancement, changes in market demand, and international competition, Weir Pharmaceutical continues to strengthen quality control, improve product quality and safety, and meet challenges. At the same time, the company responds positively to the national “double carbon” target, promotes the application and development of synthetic lubricants, and contributes to carbon reduction. In terms of assets and liabilities, as of the end of the third quarter of 2023, Weill Pharmaceutical's total capital
Well Pharmaceutical (603351.SH) released the first three quarter results, net profit of 78.2715 million yuan, a year-on-year decrease of 0.36%
Well Pharmaceutical (603351.SH) released its report for the third quarter of 2023. The company achieved operating income of 8 in the first three quarters...
Shen Jiusi, a shareholder of Weir Pharmaceutical (603351.SH), reduced his holdings of the company by a total of 268,500 shares
Weir Pharmaceutical (603351.SH) issued an announcement. As of the announcement date, the current holdings reduction plan period has expired, and shareholders are in the mood...
Will Pharmaceutical (603351.SH) released first-half results, with net profit of 53.3864 million yuan, a year-on-year decrease of 12.14%
Weir Pharmaceutical (603351.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
The Recent 9.9% Gain Must Have Brightened CEO Renrong Wu's Week, Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Most Bullish Insider
Key Insights Significant insider control over Nanjing Well Pharmaceutical GroupLtd implies vested interests in company growth 52% of the business is held by the top 5 shareholders Using data from
Following Recent Decline, Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Top Shareholder CEO Renrong Wu Sees Holdings Value Drop by 12%
If you want to know who really controls Nanjing Well Pharmaceutical Group Co.,Ltd. (SHSE:603351), then you'll have to look at the makeup of its share registry. With 53% stake, individual insiders pos
Here's Why Nanjing Well Pharmaceutical GroupLtd (SHSE:603351) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) lackluster earnings report last week. We think that the softer headline numbers might be getting coun
Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Most readers would already be aware that Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) stock increased significantly by 18% over the past week. But the company's key financial indicators appe
Be Wary Of Nanjing Well Pharmaceutical GroupLtd (SHSE:603351) And Its Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that,
Is Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Shareholder Ownership Skewed Towards Insiders?
The big shareholder groups in Nanjing Well Pharmaceutical Group Co.,Ltd. (SHSE:603351) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge compani
Analysis on the limit of Weir Pharmaceutical Co., Ltd. On January 12
Will Pharmaceutical rose to close at 36.66 yuan. The stock rose by the daily limit at 10:04, but did not open the limit. The closing capital was 33.3569 million yuan, accounting for 1.52% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 11.8793 million yuan, the net inflow of hot capital was 6.5658 million yuan, and the net outflow of retail funds was 8.8155 million yuan. The capital flow in the past 5 days is shown in the following table: this article is compiled by the Securities Star data Center according to the public data, and does not constitute investment opinions or suggestions. If you have any questions, please contact us.
KuaiBao: will Pharmaceutical (603351) blocked the trading limit at 10:04 on January 12th.
On January 12, on the intraday news, 10:04 will Pharmaceutical (603351) sealed the trading limit. The current price is 36.66, up 9.99%. The chemical pharmaceuticals of the plate to which it belongs are currently on the rise. The leading stock is Haichen Pharmaceutical Co., Ltd. Weir Pharmaceutical's main indicators and industry rankings are as follows: Weir Pharmaceutical (603351) Stock profile: this article is compiled by Securities Star data Center according to public data, and does not constitute investment opinions or suggestions. If you have any questions, please contact us.
News flash: will Pharmaceutical fell by the limit at 35.64 yuan.
China Finance Online Co Ltd news on January 5, today will Pharmaceutical opened at 39.46 yuan, as of 10:24, the stock fell 10% to 35.64 yuan, sealed the limit. Yesterday (2022-01-04) the net inflow of the stock was 6.84 million yuan, the main net inflow was 4.2977 million yuan, the net inflow of China alone was 599900 yuan, and the net inflow of retail investors was 1.9425 million yuan. (for real-time capital flows, please click.) in the last month, will Pharmaceutical has been on the Dragon and Tiger list for a total of 0 times, indicating that will Pharmaceutical shares are not active. (for more enquiries on the Dragon and Tiger list, please click)
Analysis
Price Target
No Data
